TITLE

CLINIC ROUNDUP

PUB. DATE
May 2009
SOURCE
BioWorld Today;5/1/2009, Vol. 20 Issue 83, p8
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
This section offers news briefs on clinical trials. Results from Can-Fite BioPharma's Phase IIb study in rheumatoid arthritis patients indicate that the study failed to achieve its primary efficacy endpoint. XOMA Ltd. has completed patient enrollment in its Phase I study of XOMA 052 which targets the inflammatory cause of Type II diabetes. Rockwell Medical Technologies has completed its patient enrollment for its ongoing Phase IIb dose-ranging study for its iron deficiency anemia drug soluble ferric pyrophosphate (SFP).
ACCESSION #
38708566

 

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics